This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Pancreatic Cancer
and you are
between 18 and 75
years old
This is an advanced phase trial assessing
the effectiveness of the new treatment before being released on the market.
Show me locations

The purpose

Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III study of neoadjuvant chemoradiation with gemcitabine in patients with borderline resectable pancreas cancer. The study is designed in 2 arms, one with upfront surgery and the other with neoadjuvant chemoradiation therapy.

Provided treatments

  • Drug: Neoadjuvant chemoradiation
  • Procedure: Upfront surgery

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01458717. The sponsor of the trial is Seoul National University Hospital and it is looking for 58 volunteers for the current phase.
Official trial title:
Multicenter Prospective Randomized Phase II/III Study of Neoadjuvant Chemoradiation With Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer